Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Vincent J. Picozzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0002-3493-7769; OpenAlex author ID A5039034056. Sources: ClinicalTrials.gov.

Their work

Papers
35 (first author 5, last author 4)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
132
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 3 papers · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 3 papers · 2016: 1 paper · 2017: 4 papers · 2018: 4 papers, 2 trials · 2019: 4 papers · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 35

  1. Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients. First author DOI 10.1080/13696998.2026.2707046↗
  2. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… First author DOI 10.1200/jco-25-00746↗
  3. Treatment of advanced pancreatic cancer: When will the third time be a charm? Co-author DOI 10.1002/cncr.35499↗
  4. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  5. Pancreatic cancer: new approaches to drug therapy. Co-author DOI 10.1097/js9.0000000000000877↗
  6. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… First author DOI 10.1002/cam4.6621↗
  7. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Co-author DOI 10.1093/oncolo/oyad080↗
  8. Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Sa… Last author DOI 10.3390/cancers15235588↗
  9. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Co-author DOI 10.1002/cam4.4768↗
  10. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1136/esmoopen-2019-000668↗
  11. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Co-author DOI 10.1634/theoncologist.2019-0878↗
  12. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0440↗
  13. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  14. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Last author DOI 10.1089/pancan.2019.0012↗
  15. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… First author DOI 10.1158/1078-0432.ccr-18-2992↗
  16. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy. Co-author DOI 10.1186/s12014-019-9251-3↗
  17. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? Co-author DOI 10.1002/jso.25060↗
  18. Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.03.014↗
  19. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  20. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival? Co-author DOI 10.1245/s10434-018-6334-8↗
  21. Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s12029-016-9902-9↗
  22. Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Last author DOI 10.1016/j.amjsurg.2016.04.008↗
  23. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Co-author DOI 10.1245/s10434-016-5716-z↗
  24. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Kno… Co-author DOI 10.18632/oncotarget.13225↗
  25. Using Experience-Based Design to Improve the Care Experience for Patients With Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.011213↗
  26. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  27. Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancre… Co-author DOI 10.1016/j.gie.2015.01.026↗
  28. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  29. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  30. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with pre… First author DOI 10.1186/2051-1426-2-s3-p68↗
  31. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Co-author DOI 10.1245/s10434-014-3486-z↗
  32. Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. Last author DOI 10.1097/coc.0b013e31823a53ce↗
  33. Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience. Co-author DOI 10.1016/j.gie.2011.04.029↗
  34. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACO… Co-author DOI 10.1093/annonc/mdq384↗
  35. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 t… Co-author DOI 10.1245/s10434-010-1282-y↗

Trials 3

  1. Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer Principal investigator NCT03703063↗
  2. Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology Principal investigator NCT03703089↗
  3. Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT Principal investigator NCT00761241↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adnan A. Alseidi · 8 shared papers, 2014–2020 · strength 0.61
  2. Flavio G. Rocha · 8 shared papers, 2014–2020 · strength 0.61
  3. Lynn McCormick Matrisian · 4 shared papers, 2017–2024 · strength 0.47
  4. Bruce C. M. Wang · 1 shared paper, 2026 · strength 0.43
  5. Gregory F. Guzauskas · 1 shared paper, 2026 · strength 0.43
  6. Andrea Wang‐Gillam · 6 shared papers, 2013–2022 · strength 0.40
  7. William Scott Helton · 5 shared papers, 2016–2020 · strength 0.39
  8. Richard A. Kozarek · 6 shared papers, 2011–2018 · strength 0.35
  9. Brett Schroeder · 1 shared paper, 2023 · strength 0.31
  10. Andrew Eugene Hendifar · 3 shared papers, 2017–2024 · strength 0.30
  11. Jordan D. Berlin · 2 shared papers, 2020–2023 · strength 0.28
  12. Vincent M. Chung · 3 shared papers, 2017–2022 · strength 0.26
  13. Allyson J. Ocean · 3 shared papers, 2015–2022 · strength 0.26
  14. Stephen Y. Oh · 4 shared papers, 2015–2018 · strength 0.25
  15. Hedy Lee Kindler · 2 shared papers, 2019–2023 · strength 0.24
  16. Emanuel F. Petricoin · 2 shared papers, 2018–2024 · strength 0.24
  17. Scott W. Helton · 4 shared papers, 2014–2018 · strength 0.24
  18. Philip A. Philip · 2 shared papers, 2019–2022 · strength 0.23
  19. Michael Jon Pishvaian · 3 shared papers, 2017–2020 · strength 0.22
  20. Erkut Hasan Borazanci · 2 shared papers, 2019–2020 · strength 0.18
  21. Lucia Roa‐Peña · 1 shared paper, 2024 · strength 0.17
  22. Brent K. Larson · 1 shared paper, 2024 · strength 0.17
  23. Lyanne Delgado Coka · 1 shared paper, 2024 · strength 0.17
  24. Minsig Choi · 1 shared paper, 2024 · strength 0.17
  25. Luisa F. Escobar‐Hoyos · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.